Experiencia clínica sobre la eficacia y la seguridad de GLICLAZIDA MR en el tratamiento de Diabetes Mellitus Tipo 2 / Clinical Experience of effectiveness and security of GLICLAZID MR’S in the treatment of Diabetes Mellitus Type 2

RESUMEN

Estudio realizado en los hospitales Teodoro Maldonado Carbo (IESS-Regional 2) y Seguro Social de Milagro; desde marzo a noviembre del 2001. Fueron reclutados 27 pacientes divididos en dos grupos Grupo I (de reciente diagnóstico) y Grupo II (pacientes ya manejados) para tratamiento farmacológico único de diabetes tipo II con Gliclazida MR.Objetivo: Verificar la eficacia y la seguridad de Gliclazida MR en pacientes diabéticos Tipo 2 recién pesquizados y ya conocidos, estos últimos controlados con antidiabéticos orales.Resultados: La Gliclazida MR redujo la glucosa plasmática en los dos grupos (Grupo I 292mg/dl como glicemia media inicial y 10.7 de HbA1c media inicial vs. 122mg/dl glicemia media final y 7.1% de HbA1c media final. Grupo II 181mg/dl de glicemia media inicial y 9.6% de HbA1c media inicial vs. 116mg7dl glicemia media final y 7.4% de HbA1c final). No hubo diferencias significativas en los parámetros hepáticos de control, ni en los perfiles de peso durante el estudio; ningún paciente presentó datos clínicos compatibles con Hipoglicemia.Conclusión: La eficiencia y la seguridad de Gliclazida MR como una nueva opción farmacológica, fue comprobada.

ABSTRACT

A prospective study done at the Teodoro Maldonado Carbo’s Hospital (IESS-Regional 2) and the Milagro’s Social Security Hospital during the period between the months of March through November of 2001. We studied 27 patients divided in two groups Group I (recently diagnosed) and Group II (which have received pharmacological treatment) that were to be treated with Gliclazid MR a unique pharmacological treatment for their diabetes type II.Objectives: Evaluate the effectiveness and security of the Gliclazid MR on the cases of diabetics type II, recently discovered and on other patients that have been controlled with oral antidiabetic agents.Results: Gliclazid MR reduced the plasmatic glucose level in the two studied groups. (Group I from 292 mg/dl of average initial plasmatic glucose level and 10.7 of HbA1c initial average vs 122mg/dl of final average plasmatic glucose and 7.1% of HbA1c final average. Group II from 181mg/dl of initial average of the plasmatic glucose level and 9.6% of HbA1c initial average to 116mg/dl and 7.4% of HbA1c final average). We didn’t fine differences in the control of hepatic parameters of control during the study and none of the patient’s clinical reports signs or symptoms of Hypoglycemia.Conclusion: The effectiveness and the security of the Gliclazid MR were proved.